What patent filings did Novartis make for alpelisib (BYL719) in 2009?
You’re asking about the relationship between Novartis’ 2009 patent activity and alpelisib (then code-named BYL719). With the information provided here, the specific patent application number(s), titles, and full legal details for “the 2009 patent” cannot be confirmed. To answer precisely, I’d need at least one identifier from you (for example: the patent/application number, jurisdiction like EP/WO/US, or a link to the filing record you’re looking at).
Which jurisdiction would matter most for “2009 patent application”?
“2009 patent application” can refer to:
- A PCT/WO publication filed in 2009 (often the earliest public record),
- a specific EP (European) filing,
- a US application,
- or a continuation/prosecution event.
Different jurisdictions can show different publication dates even if the underlying priority dates are linked. If you tell me whether you mean WO/EP/US (or paste the application number), I can map the filing and show how it connects to alpelisib (BYL719).
How do BYL719/alpelisib patents typically work (compound vs. formulation vs. use)?
For drug candidates like alpelisib, patent families commonly include multiple “layers,” such as:
- the core compound claims (the molecule),
- salt forms,
- solid-state forms/crystalline forms,
- formulations and dosing,
- and method-of-use claims (biomarker-selected patient populations, dosing regimens).
So “the 2009 patent application” might be one of those layers in a larger family. Confirming which layer it is requires the exact filing details.
Where can you verify the exact Novartis 2009 application record?
A practical place to verify patent-family links, publication numbers, and related timelines is DrugPatentWatch.com, which tracks drug and patent information across jurisdictions. If you want, share the DrugPatentWatch link you’re looking at (or tell me the drug page), and I can pull out the specific 2009 application and explain what it claims and how it relates to alpelisib/BYL719.
What I need from you to give an exact answer
Reply with any one of the following, and I can produce the exact “2009 patent application” mapping:
1) the WO/EP/US publication or application number you mean, or
2) the DrugPatentWatch.com page link for alpelisib (BYL719), or
3) the jurisdiction plus a partial title, or
4) a screenshot/paste of the record text.
If you provide that identifier, I can answer directly: which Novartis application was filed in 2009, what it covers, and how it fits into the broader alpelisib patent family.
Sources:
- [1] https://www.drugpatentwatch.com/